IPS Biopharma
SHARE
IPS Biopharma AG is a privately held, Swiss immuno-oncology focused biotech company developing a potentially first-in-class immunotherapy for solid tumor cancers. The company’s lead drug candidate, IP-001, is designed to initiate a patient-specific, well-tolerated, systemically active immune response against a patient’s individual cancer. IP-001, also known as N-dihydrogalactochitosan, is injected intratumorally after a standard-of-care tumor ablation to initiate the immunotherapy. Unique molecular properties and the novel mechanism of action enables IP-001 to trap and retain tumor-targeting information and promote a robust immune response that attacks both the ablated tumor and distant metastases.

Encouraging early clinical data showed shrinkage of both local tumors and distant metastases after ablation + IP-001 treatment. In some patients, this led to elimination of the cancer with long-lasting response. The company has partnered with the Swiss Group for Clinical Cancer Research (SAKK) for clinical trial development and implementation of its Swiss phase I/II multicenter study that addresses significant clinical unmet need in various indications.

IPS Biopharma AG is an Immunophotonics subsidiary and is supported by the Swiss Foundation for Technological Innovation (STI), be-advanced, the Berne Economic Development Agency (BEDA), is located in the Switzerland Innovation Park and is an active part of the startup community in Switzerland.

Mehr News & Events

Smart Factory Breakfast Pitch

Kurz vor den Sommerferien fand bereits der dritte Smart Factory Breakfast Pitch in der Swiss Smart Factory statt.

3rd International Smart Factory Summit

Der dritte "International Smart Factory Summit" stand unter dem Motto “Rewiring Global Value Chains and Production Networks for Resiliency and Sust...

Startup Weekend Biel/Bienne 2022

That was Startup Weekend Biel/Bienne 2022!

This website uses cookies to ensure you get the best experience on our website. By continuing you agree with the our terms of use.